Best of ASCO - 2014 Annual Meeting



Attend this session at the
2017 ASCO Annual Meeting!

Session: Head and Neck Cancer

Type: Oral Abstract Session

Time: Monday June 5, 8:00 AM to 11:00 AM

Location: S100a

LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).


Head and Neck Cancer

2017 ASCO Annual Meeting

Abstract No:

J Clin Oncol 35, 2017 (suppl; abstr 6001)

Author(s): Barbara Burtness, Robert I. Haddad, José Dinis, Jose Manuel Trigo Perez, Tomoya Yokota, Luciano De Souza Viana, Ilya Romanov, Jan Baptist Vermorken, Jean Bourhis, Makoto Tahara, J.G.M. Segalla, Amanda Psyrri, Irina Vasilevskaya, Chaitali Singh Nangia, Manuel Chaves-Conde, Bushi Wang, Neil Gibson, Eva Ehrnrooth, Kevin Harrington, Ezra E.W. Cohen, On Behalf of the LUX-Head and Neck 2 Investigators; Yale School of Medicine, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Instituto Português de Oncologia de Lisboa, Porto, Portugal; Hospital Virgen de la Victoria, Malaga, Spain; Shizuoka Cancer Center, Shizuoka, Japan; Hospital Marcio Cunha, Ipatinga, Brazil; Russian Oncological Research Centre, Moscow, Russia; Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Hospital Amaral Carvalho, Jau, Brazil; University General Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece; Oncology Center of Moskovskiy, St. Petersburg, Russian Federation; University of California Irvine Comprehensive Cancer Center, Orange, CA; Hospital Virgen del Rocío, Seville, Spain; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany; TA Oncology, Boehringer Ingelheim, Denmark A/S, Copenhagen, Denmark; The Institute of Cancer Research, London, United Kingdom; University of California, San Diego, La Jolla, CA

Abstract Disclosures


Background: Locally advanced HNSCC is treated curatively, but recurrence is common. In HNSCC, EGFR is richly expressed and EGFR inhibition is validated treatment (tx); the ErbB family blocker afatinib (A) showed efficacy in recurrent/metastatic disease. This Phase III trial assessed if A after definitive CRT improves disease-free survival (DFS). Methods: Eligible pts had complete response after CRT ≥66 Gy (or equivalent) with concurrent cisplatin or carboplatin but not prior EGFR inhibition, for HNSCC of oral cavity, hypopharynx, larynx, or oropharynx with >10 pack years (pk yrs) tobacco use. Pts were stratified by ECOG PS (0/1) and nodal stage (N0–2a/N2b–3), and randomized 2:1 to A 40 mg/d or placebo (P); tx continued for 18 m if tolerated, or until disease recurrence. The primary endpoint was DFS. Results: Of 669 pts planned, 617 were randomized; A 411, P 206. Median age was 58 yrs; 86% were male; 65% ECOG PS 0; most had smoked (A/P ex-smoker: 66/72%; current: 28/22%). Subsites (A/P) were: oropharynx 53/54%; hypopharynx 21/23%; larynx 18/12%; oral cavity 9/10%. The majority had T3 or 4 (A/P 70/68%) and N2 disease (67/63%). Accrual was halted for futility on independent DMC recommendation: at a pre-planned interim analysis (40% of DFS events), median DFS was A 43.4 m vs P not reached (NR; HR 1.13 [95% CI 0.81–1.57], p=0.48); the Table shows key subgroups. Median treatment duration was A 300.0 d, P 455.5 d. Recurrence was A 23%, P 23%. Dose reduction of A was required in 53% (mostly due to diarrhea, stomatitis). Tx was discontinued due to AEs in A 15%, P 4%. Conclusions: A after CRT did not improve DFS vs P. Subgroup analyses were underpowered to provide definitive conclusions. Harrington and Cohen contributed equally. Clinical trial information: NCT01345669

Median DFS, m
HR, A vs P [95% CI]
positive5341NRNR1.16 [0.41–3.25]
negative13561NR40.10.75 [0.44–1.26]
>1505232NRNR0.78 [0.33–1.86]
≤1503022NRNR2.52 [0.80–7.92]
Nodal stage
N0–N2a1598337.4NR2.23 [1.18–4.22]
N2b–N325212343.440.10.82 [0.55–1.21]
Tobacco, pk yrs
<104218NR25.60.54 [0.21–1.42]
≥1036818843.4NR1.26 [0.88–1.79]

Other Abstracts in this Sub-Category:


1. Developing and validating a multivariable predictive biomarker for treatment selection for oropharyngeal squamous cell carcinoma: The PREDICTR-OPC study.

Meeting: 2017 ASCO Annual Meeting Abstract No: 6004 First Author: Hisham Mohamed Mehanna
Category: Head and Neck Cancer - Local-Regional


2. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979).

Meeting: 2017 ASCO Annual Meeting Abstract No: 6006 First Author: Hu Liang
Category: Head and Neck Cancer - Local-Regional


3. Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.

Meeting: 2017 ASCO Annual Meeting Abstract No: 6007 First Author: Vanita Noronha
Category: Head and Neck Cancer - Local-Regional